PDCD1 and melanoma: The synergistic potential of CVA21 delivered both intratumorally and intravenously in combination with systemic pembrolizumab versus pembrolizumab alone in anti-PD-1-naïve stage III-IV melanoma is under phase 2 investigation (NCT04152863) (Table 1).